Monitoring Report: Respiratory Viruses - August 2024 Data ========================================================= * Samuel Gratzl * Brianna M Goodwin Cartwright * Patricia J Rodriguez * Charlotte Baker * Duy Do * Nicholas L Stucky ## Abstract **Background** Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus. **Objective** This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through the last full week of August 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over). **Methods** Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and August 25, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults. **Results** We included 642,821 hospitalizations of 592,200 unique patients who tested positive for a respiratory virus between October 01, 2019 and August 25, 2024. Overall, the rate of hospitalizations associated with respiratory viruses remained stable throughout August 2024, with no change compared to July 2024. COVID-associated hospitalizations saw a slight decrease of 2.9%, while influenza-associated hospitalizations dropped significantly by 57.4%. Other respiratory viruses, including HMPV and RSV, reported no hospitalizations during this period, although rhinovirus-associated hospitalizations increased by 61.7%. In the last week of August 2024, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations. For August, test positivity for COVID is high (20.9%) but falling (-5.3%). Test positivity for rhinovirus is high (15.1%) and rising through August (+63.9%). For other viruses, test positivity is relatively low with parainfluenza having the next highest test positivity at 1.4%. No other viruses have a rising test positivity. **Discussion** The data indicates that respiratory virus-associated hospitalizations have stabilized at low levels during August 2024, following a trend of decreasing rates observed earlier in the year. The notable decrease in influenza-associated hospitalizations suggests a continued decline in this virus’s impact. In contrast, the increase in rhinovirus-associated hospitalizations highlights its growing significance in the current respiratory virus landscape. ![Figure1](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F1.medium.gif) [Figure1](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F1) **Overall population**For the overall population, the rate of hospitalizations associated with respiratory viruses remained unchanged in August 2024 compared to July 2024. The slight decrease in COVID-associated hospitalizations (-2.9%) and the significant drop in influenza-associated hospitalizations (-57.4%) counterbalanced the significant increase in rhinovirus-associated hospitalizations (+61.7%). In the last week of August, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations. For August, test positivity for COVID is high (20.9%) but falling (-5.3%). Test positivity for rhinovirus is high (15.1%) and rising (+63.9%). For other viruses, test positivity is relatively low with parainfluenza having the next highest test positivity at 1.4%. No other viruses have a rising test positivity. ![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F2/graphic-2.medium.gif) [](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F2/graphic-2) ![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F2/graphic-3.medium.gif) [](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F2/graphic-3) **Infants and children (age 0-4)**In the population aged 0-4 years, respiratory virus-associated hospitalizations increased significantly by 40.6% throughout August 2024. This rise was primarily driven by increases in rhinovirus-associated hospitalizations, which rose by 80.9%. In the last week of August, 2.4% of all hospitalizations in this age group were associated with a respiratory virus, with rhinovirus being the largest contributor at 1.8%. For August, test positivity for COVID is high (19.4%), but peaked in August and is falling (-7.5%). Test positivity for rhinovirus is high (42.1%) and rising (+30.7%). For other viruses, test positivity is lower, with parainfluenza having the next highest test positivity at 3.3%. No other viruses have a rising test positivity. ![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F3/graphic-4.medium.gif) [](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F3/graphic-4) ![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F3/graphic-5.medium.gif) [](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F3/graphic-5) **Older adults (age 65 and over)**Among older adults (age 65 and over), there was a slight decrease of 4.7% in hospitalizations associated with respiratory viruses in August 2024 compared to July 2024. COVID-associated hospitalizations remained stable, while influenza-associated hospitalizations saw a significant decline of 62.9%. In the last week of August, respiratory virus-associated hospitalizations accounted for 3.4% of all hospitalizations in this age group, with COVID remaining a consistent contributor. For August, test positivity for COVID is high (21.8%) but falling (-4.1%) compared to the last week of July. Rhinovirus has the next highest test positivity at 4.0%, which has been rising throughout August (+20.6%). ## Introduction COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness, such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death, especially in vulnerable populations such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce. Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma. Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014). It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted. This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports. ## Methods ### Data We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and August 25, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on September 09, 2024 and included de-identified patient care data primarily located across ten states: California, New York, Florida, Illinois, Ohio, Washington, Arizona, North Carolina, Wisconsin, and Louisiana. ### Population We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year. ### Hospitalization rate analysis Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over). Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates. Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below. ### Test positivity rate analysis Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month. Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below. ## Results ### Overall population Our study population consists of 642,821 hospitalizations of 592,200 unique patients (Table 1). View this table: [Table 1:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T1) Table 1: Patient characteristics by season. #### Hospitalization rate over time The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses. ![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F4.medium.gif) [Figure 1:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F4) Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 ![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F5.medium.gif) [Figure 2:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F5) Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 #### Test positivity rate over time We included 45,736,336 lab results with known results of which 4,378,059 were positive. The test positivity rate is shown in Figure 3. ![Figure 3:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F6.medium.gif) [Figure 3:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F6) Figure 3: Weekly test positivity rate since October 2019 ### COVID-19 Our COVID study population consists of 456,981 hospitalizations of 439,700 unique patients (Table 2). View this table: [Table 2:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T2) Table 2: COVID patient characteristics by season. #### Hospitalization rate over time The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends. ![Figure 4:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F7.medium.gif) [Figure 4:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F7) Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019 ![Figure 5:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F8.medium.gif) [Figure 5:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F8) Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season #### Test positivity rate over time We included 25,438,197 COVID lab results with known results of which 2,928,081 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends. ![Figure 6:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F9.medium.gif) [Figure 6:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F9) Figure 6: Weekly COVID test positivity rate since October 2019 ![Figure 7:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F10.medium.gif) [Figure 7:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F10) Figure 7: Weekly COVID test positivity rate by season ### Influenza Our influenza study population consists of 59,425 hospitalizations of 51,218 unique patients (Table 3). View this table: [Table 3:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T3) Table 3: Influenza patient characteristics by season. #### Hospitalization rate over time The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends. ![Figure 8:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F11.medium.gif) [Figure 8:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F11) Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019 ![Figure 9:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F12.medium.gif) [Figure 9:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F12) Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season #### Test positivity rate over time We included 11,158,538 influenza lab results with known results of which 879,003 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends. ![Figure 10:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F13.medium.gif) [Figure 10:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F13) Figure 10: Weekly influenza test positivity rate since October 2019 ![Figure 11:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F14.medium.gif) [Figure 11:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F14) Figure 11: Weekly influenza test positivity rate by season ### Human metapneumovirus (HMPV) Our HMPV study population consists of 15,048 hospitalizations of 10,768 unique patients (Table 4). View this table: [Table 4:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T4) Table 4: HMPV patient characteristics by season. #### Hospitalization rate over time The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends. ![Figure 12:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F15.medium.gif) [Figure 12:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F15) Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2019 ![Figure 13:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F16.medium.gif) [Figure 13:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F16) Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season #### Test positivity rate over time We included 1,440,685 HMPV lab results with known results of which 41,096 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends. ![Figure 14:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F17.medium.gif) [Figure 14:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F17) Figure 14: Weekly HMPV test positivity rate since October 2019 ![Figure 15:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F18.medium.gif) [Figure 15:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F18) Figure 15: Weekly HMPV test positivity rate by season ### Parainfluenza virus Our parainfluenza virus study population consists of 14,842 hospitalizations of 12,214 unique patients (Table 5). View this table: [Table 5:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T5) Table 5: Parainfluenza virus patient characteristics by season. #### Hospitalization rate over time The rate of parainfluenza virus-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends. ![Figure 16:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F19.medium.gif) [Figure 16:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F19) Figure 16: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions since October 2019 ![Figure 17:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F20.medium.gif) [Figure 17:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F20) Figure 17: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions by season #### Test positivity rate over time We included 1,539,148 parainfluenza virus lab results with known results of which 59,776 were positive. The parainfluenza virus test positivity rate is shown in Figure 18. Figure 19 shows yearly trends. ![Figure 18:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F21.medium.gif) [Figure 18:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F21) Figure 18: Weekly parainfluenza virus test positivity rate since October 2019 ![Figure 19:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F22.medium.gif) [Figure 19:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F22) Figure 19: Weekly parainfluenza virus test positivity rate by season ### Respiratory syncytial virus (RSV) Our RSV study population consists of 34,850 hospitalizations of 27,514 unique patients (Table 6). View this table: [Table 6:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T6) Table 6: RSV patient characteristics by season. #### Hospitalization rate over time The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends. ![Figure 20:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F23.medium.gif) [Figure 20:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F23) Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2019 ![Figure 21:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F24.medium.gif) [Figure 21:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F24) Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season #### Test positivity rate over time We included 4,685,800 RSV lab results with known results of which 232,834 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends. ![Figure 22:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F25.medium.gif) [Figure 22:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F25) Figure 22: Weekly RSV test positivity rate since October 2019 ![Figure 23:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F26.medium.gif) [Figure 23:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F26) Figure 23: Weekly RSV test positivity rate by season ### Rhinovirus Our rhinovirus study population consists of 61,675 hospitalizations of 50,786 unique patients (Table 7). View this table: [Table 7:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T7) Table 7: Rhinovirus patient characteristics by season. #### Hospitalization rate over time The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends. ![Figure 24:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F27.medium.gif) [Figure 24:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F27) Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019 ![Figure 25:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F28.medium.gif) [Figure 25:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F28) Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season #### Test positivity rate over time We included 1,473,968 rhinovirus lab results with known results of which 237,269 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends. ![Figure 26:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F29.medium.gif) [Figure 26:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F29) Figure 26: Weekly rhinovirus test positivity rate since October 2019 ![Figure 27:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F30.medium.gif) [Figure 27:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F30) Figure 27: Weekly rhinovirus test positivity rate by season ### Infants and children (age 0-4) Our infants and children study population consists of 44,011 hospitalizations of 33,993 unique patients (Table 8). View this table: [Table 8:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T8) Table 8: Infants and children patient characteristics by season. #### Hospitalization rate over time The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses. ![Figure 28:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F31.medium.gif) [Figure 28:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F31) Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five ![Figure 29:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F32.medium.gif) [Figure 29:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F32) Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five #### Test positivity rate over time We included 4,850,529 lab results with known results of infants and children under age five. Of those tests, 563,330 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30. ![Figure 30:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F33.medium.gif) [Figure 30:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F33) Figure 30: Weekly test positivity rate since October 2019 for infants and children under five ### Older adults (age 65 and over) Our older adults study population consists of 338,698 hospitalizations of 315,041 unique patients (Table 9). View this table: [Table 9:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/T9) Table 9: Older adults patient characteristics by season. #### Hospitalization rate over time The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses. ![Figure 31:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F34.medium.gif) [Figure 31:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F34) Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older ![Figure 32:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F35.medium.gif) [Figure 32:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F35) Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older #### Test positivity rate over time We included 13,340,098 lab results with known results of adults aged 65 and over. Of those tests, 940,503 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33. ![Figure 33:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/09/18/2024.01.20.24301528/F36.medium.gif) [Figure 33:](http://medrxiv.org/content/early/2024/09/18/2024.01.20.24301528/F36) Figure 33: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older ## Discussion and conclusion For the overall population, the rate of hospitalizations associated with respiratory viruses remained unchanged in August 2024 compared to July 2024. The slight decrease in COVID-associated hospitalizations (-2.9%) and the significant drop in influenza-associated hospitalizations (-57.4%) contributed to this stability. In the last week of August, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations. For August, test positivity for COVID is high (20.9%) but falling (-5.3%). Test positivity for rhinovirus is high (15.1%) and rising through August (+63.9%). For other viruses, test positivity is relatively low with parainfluenza having the next highest test positivity at 1.4%. No other viruses have a rising test positivity. In the population aged 0-4 years, respiratory virus-associated hospitalizations increased significantly by 40.6% throughout August 2024. This rise was primarily driven by increases in rhinovirus-associated hospitalizations, which rose by 80.9%. In the last week of August, 2.4% of all hospitalizations in this age group were associated with a respiratory virus, with rhinovirus being the largest contributor at 1.8%. Among older adults (age 65 and over), there was a slight decrease of 4.7% in hospitalizations associated with respiratory viruses in August 2024 compared to July 2024. COVID-associated hospitalizations remained stable, while influenza-associated hospitalizations saw a significant decline of 62.9%. In the last week of August, respiratory virus-associated hospitalizations accounted for 3.4% of all hospitalizations in this age group, with rhinovirus remaining a consistent contributor. Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed September 09, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual’s electronic health record or that it was excluded from the data to protect an individual’s identity as a part of Truveta’s commitment to privacy (Truveta, 2024). We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations. ## Data Availability The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com. ## Footnotes * We updated the data till end of August 2024. * Received January 20, 2024. * Revision received September 18, 2024. * Accepted September 18, 2024. * © 2024, Posted by Cold Spring Harbor Laboratory This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/) ## References 1. Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865–870. doi:10.1067/mpd.2000.110531 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1067/mpd.2000.110531&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11113845&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F09%2F18%2F2024.01.20.24301528.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000165876300021&link_type=ISI) 2. Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. [https://www.cdc.gov/flu/about/burden/past-seasons.html](https://www.cdc.gov/flu/about/burden/past-seasons.html) 3. Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. [https://www.cdc.gov/surveillance/nrevss/index.html](https://www.cdc.gov/surveillance/nrevss/index.html) 4. Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. [https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm](https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm) 5. Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. [https://www.cdc.gov/rsv/research/rsv-net/dashboard.html](https://www.cdc.gov/rsv/research/rsv-net/dashboard.html) 6. Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., … Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620–e638. doi:10.1542/peds.2014-1666 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1542/peds.2014-1666&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25070304&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F09%2F18%2F2024.01.20.24301528.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000340266000042&link_type=ISI) 7. Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, doi:10.1093/ofid/ofz225 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ofid/ofz225&link_type=DOI) 8. Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. doi:10.1093/cid/cit471 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/cit471&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23876395&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F09%2F18%2F2024.01.20.24301528.atom) 9. Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. doi:10.1093/ofid/ofw270 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ofid/ofw270&link_type=DOI) 10. Shi, T., McAllister, D. A., O’Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., … Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. doi:10.1016/S0140-6736(17)30938-8 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(17)30938-8&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28689664&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F09%2F18%2F2024.01.20.24301528.atom) 11. Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447–2455. doi:10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.vaccine.2023.02.038&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=36803895&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F09%2F18%2F2024.01.20.24301528.atom) 12. Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511–1518. doi:10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/cix1060&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29206909&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F09%2F18%2F2024.01.20.24301528.atom) 13. Truveta. (2024). Truveta’s Approach to Patient Privacy. [https://resources.truveta.com/patient-privacy](https://resources.truveta.com/patient-privacy)